Clinical trials: Asthma; Eosinophilic
Dactinomycin Adverse Reaction, Bone and Joint Infection
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
- Trial name
- PKTOXDAP (NCT04933344)
- Testing
- patients having had BJI or PJI treated with daptomycin
- Where
- France
- Volunteers
- 1,130 people
- Sponsor
- Hospices Civils de Lyon
Uncontrolled and Suspected Eosinophilic Asthma
A Phase IIa Study of KHK4563
This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma exacerbation rate in adult subjects with uncontrolled…
- Trial name
- 4563-003 (NCT01412736)
- Testing
- KHK4563
- Where
- 29 sites in Japan, South Korea
- Volunteers
- 106 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Asthma; Eosinophilic
The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma
The study aim is to look at the effect of the regular use of inhaled corticosteroids on the response and received from mepolizumab treatment which you are receiving or had received before.
- Trial name
- CSAREA (NCT05241769)
- Volunteers
- 250 people
- Sponsor
- University Hospital Birmingham
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Asthma
Blood Leukocyte Profiling in Eosinophilic Type 2 Asthma: Influence of Systemic IL-5 Targeting
The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5…
- Trial name
- NCT05689931
- Testing
- Mepolizumab, Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
- Where
- Sweden
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Region Skane
Asthma
Step-down of Inhaled Corticosteroids (ICS) in Non-eosinophilic Asthmatics
There is growing evidence that non-eosinophilic asthmatics are less sensitive to inhaled corticosteroids (ICS) than eosinophilic asthmatics.
- Trial name
- NCT02169323
- Testing
- Step-down
- Where
- Belgium
- Volunteers
- 43 people
- Sponsor
- Renaud Louis
Asthma; Eosinophilic
Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
This study is aimed at evaluation of the efficacy of mepolizumab 100 mg subcutaneously (SC) every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma…
- Trial name
- NCT05091385
- Testing
- Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019
- Where
- Poland
- Volunteers
- 106 people
- Sponsor
- Medical University of Lodz
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as…
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- ROSY-F (NCT07444567)
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference…
- Trial name
- NCT01634620
- Testing
- NIOX MINO® Instrument (09-1100)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Aerocrine AB
Asthma
A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
This study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
- Trial name
- NCT05584306
- Testing
- 610 30mg group, 610 100mg group, 610 300mg group
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions
The main aim of this study is to investigate the change in asthma control after 6 months of therapy in patients treated with benralizumab biologic therapy for severe eosinophilic asthma under real-life conditions in a pulmonary…
- Trial name
- imPROve (NCT04184284)
- Where
- 50 sites in Germany
- Volunteers
- 246 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who at the discretion of…
- Trial name
- ORBE (NCT04126499)
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Asthma
Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
The purpose of the MEMORY trial is to compare the effects of mepolizumab with Placebo on airway physiology in patients with eosinophilic asthma
- Trial name
- MEMORY (NCT02594332)
- Testing
- Mepolizumab
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Johannes Gutenberg University Mainz
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma; Eosinophilic
SIM0718 Treatment of Asthma Clinical Study
Phase III clinical study of SIM0718 asthma
- Trial name
- NCT06488755
- Testing
- SIM0718 injection
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Asthma Brittle
Exploring Asthma Exacerbations in Mepolizumab Treated Patients
This is a multicentre, observational study focusing on exacerbation events in patients with severe eosinophilic asthma on Mepolizumab.
- Trial name
- NCT03324230
- Where
- 4 sites in United Kingdom
- Volunteers
- 146 people
- Sponsor
- Queen's University, Belfast
Asthma
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an…
- Trial name
- REIMAGINE (NCT06041386)
- Testing
- Mepolizumab, Spirometry
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Asthma
Non-Eosinophilic Biological Effects of IL-5
This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with asthma.
- Trial name
- NCT06026202
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Severe Persistent Asthma, Eosinophilic Bronchitis
Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
The steroid sparing effect of anti interleukin (IL-5) monoclonal antibody has been proven, but the effectiveness of subcutaneous (SC) compared to intravenous (IV) administration of these drugs to suppress airway eosinophilia is…
- Trial name
- NCT02559791
- Testing
- Reslizumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis
Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
The purpose of this study is to investigate whether addition of Omalizumab enables a reduction in the dose of prednisone in patients with asthma and eosinophilic bronchitis.
- Trial name
- NCT02049294
- Testing
- Omalizumab (Xolair)
- Where
- 5 sites in Canada
- Volunteers
- 11 people
- Sponsor
- McMaster University